Alborz Omidian

Department of Psychiatry, Westchester Medical Center, Valhalla, NY 10595, USA.

2 papers in the library · 16 citations · publishing 2025

Papers

The Emergence of Psilocybin in Psychiatry and Neuroscience

Pharmaceuticals April 9, 2025 Hossein Omidian, Alborz Omidian 11 citations

Psilocybin, a naturally occurring psychedelic compound, is being re-evaluated for its potential to treat psychiatric and neurological disorders. This review examines its pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Emerging evidence supports its effectiveness for major depressive disorder, treatment-resistant depression, anxiety, alcohol use disorders, and cancer-related distress. However, significant barriers remain, including methodological limitations, regulatory hurdles, and a lack of diversity in clinical trial populations. Advances in biosynthetic production and better psychotherapeutic integration are needed for scalability. Future research should focus on long-term safety, precise dosing, and neurobiological mechanisms to refine therapeutic applications.

DOI: 10.3390/ph18040555 Psilocybin Major depressive disorder Anxiety Psychiatry +4

Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.

Pharmaceuticals (Basel, Switzerland) March 29, 2025 Hossein Omidian, Alborz Omidian 5 citations

LSD is being studied as a potential treatment for anxiety, depression, and alcohol use disorder, with clinical trials showing significant symptom reductions and lasting effects. It works by modulating serotonin 5-HT2A receptors, which affects brain networks involved in emotion and cognition. In psychedelic-assisted psychotherapy, mystical-type experiences during LSD use are linked to improved well-being. This review covers LSD's pharmacokinetics, mechanisms, and safety concerns, including cardiovascular risks, emotional vulnerability, and the risk of hallucinogen-persisting perception disorder (HPPD). Challenges include small sample sizes, variable dosing, and regulatory restrictions. Future research should focus on standardization, pharmacogenetics, and personalized treatment.

DOI: 10.3390/ph18040499 Full text LSD Clinical research Pharmacogenetics Serotonin receptors +8